论文信息 - Impact of microarray data quality on genomic data submissions to the FDA - 字舞流文

Impact of microarray data quality on genomic data submissions to the FDA

How can microarray data best be exploited and integrated into the regulatory decision-making process?

Felix W Frueh | F. Frueh

[1] Tao Han,et al. Cross-platform comparability of microarray technology: Intra-platform consistency and appropriate data analysis procedures are essential , 2005, BMC Bioinformatics.

[2] J. V. Moran,et al. Initial sequencing and analysis of the human genome. , 2001, Nature.

[3] Timothy B. Stockwell,et al. The Sequence of the Human Genome , 2001, Science.

[4] BMC Bioinformatics , 2005 .

[5] L J Lesko,et al. Pharmacogenomic-guided drug development: regulatory perspective , 2002, The Pharmacogenomics Journal.

[6] Weida Tong,et al. QA/QC: challenges and pitfalls facing the microarray community and regulatory agencies , 2004, Expert review of molecular diagnostics.